After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...